The global Prostate-Specific Membrane Antigen(PSMA) Inhibitor market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.

Prostate-Specific Membrane Antigen(PSMA) Inhibitors are a class of drugs that target specific antigens on the surface of prostate cancer cells. These inhibitors block the growth and spread of tumor cells by binding to PSMA and are often used in targeted therapy and imaging studies.

From a downstream perspective, Scientific Research accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).

Prostate-Specific Membrane Antigen(PSMA) Inhibitor leading manufacturers including TargetMol, Merck KGaA, DC Chemicals, Biorbyt, MedChemExpress, QYAOBIO, ACROBiosystems Group, Shanghai Apeptide Co, Xi'an Ruixi Biotechnology Co., Ltd., SNDPHARM TSCHNOLOFY, etc., dominate supply; the top five capture approximately % of global revenue, with TargetMol leading 2024 sales at US$ million.

Regional Outlook:

North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).

Asia‑Pacific will expand from US$ million to US$ million (CAGR  %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).

Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Prostate-Specific Membrane Antigen(PSMA) Inhibitor market, seamlessly integrating production capacity and sales performance across the value chain. It analyzes historical production, revenue, and sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.

By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.

Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.

Critical competitive intelligence profiles manufacturers—capacity, sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.

A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.

Market Segmentation

Scope of Prostate-Specific Membrane Antigen(PSMA) Inhibitor Market Report

Report Metric	Details
Report Name	Prostate-Specific Membrane Antigen(PSMA) Inhibitor Market
Segment by Type	Small Molecule Inhibitors Peptide Inhibitors Other
Segment by Application	Scientific Research Pharmaceuticals
Production by Region	North America Europe China Japan
Sales by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	TargetMol, Merck KGaA, DC Chemicals, Biorbyt, MedChemExpress, QYAOBIO, ACROBiosystems Group, Shanghai Apeptide Co, Xi'an Ruixi Biotechnology Co., Ltd., SNDPHARM TSCHNOLOFY, Hangzhou MolCore BioPharmatech
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the Prostate-Specific Membrane Antigen(PSMA) Inhibitor study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Maps global production capacity, utilization, and market share (2020–2031), identifies efficient hubs, reveals regulatory/trade policy impacts and bottlenecks.
Chapter 4: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 5: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 6: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 7: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 8: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 9: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 10: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 11: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 12: Profiles manufacturers in depth—details product specs, capacity, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 13: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint and technology, cost drivers, plus downstream channels and distributor roles.
Chapter 14: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 7–11) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 13) and customers (Chapter 6) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 4 and 12).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 13 and 14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

Who are the main players in the Prostate-Specific Membrane Antigen(PSMA) Inhibitor Market report?

Ans: The main players in the Prostate-Specific Membrane Antigen(PSMA) Inhibitor Market are TargetMol, Merck KGaA, DC Chemicals, Biorbyt, MedChemExpress, QYAOBIO, ACROBiosystems Group, Shanghai Apeptide Co, Xi'an Ruixi Biotechnology Co., Ltd., SNDPHARM TSCHNOLOFY, Hangzhou MolCore BioPharmatech

What are the Application segmentation covered in the Prostate-Specific Membrane Antigen(PSMA) Inhibitor Market report?

Ans: The Applications covered in the Prostate-Specific Membrane Antigen(PSMA) Inhibitor Market report are Scientific Research, Pharmaceuticals

What are the Type segmentation covered in the Prostate-Specific Membrane Antigen(PSMA) Inhibitor Market report?

Ans: The Types covered in the Prostate-Specific Membrane Antigen(PSMA) Inhibitor Market report are Small Molecule Inhibitors, Peptide Inhibitors, Other

1 Study Coverage

1.1 Introduction to Prostate-Specific Membrane Antigen(PSMA) Inhibitor: Definition, Properties, and Key Attributes

1.2 Market Segmentation by Type

1.2.1 Global Prostate-Specific Membrane Antigen(PSMA) Inhibitor Market Size by Type, 2020 VS 2024 VS 2031

1.2.2 Small Molecule Inhibitors

1.2.3 Peptide Inhibitors

1.2.4 Other

1.3 Market Segmentation by Application

1.3.1 Global Prostate-Specific Membrane Antigen(PSMA) Inhibitor Market Size by Application, 2020 VS 2024 VS 2031

1.3.2 Scientific Research

1.3.3 Pharmaceuticals

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Executive Summary

2.1 Global Prostate-Specific Membrane Antigen(PSMA) Inhibitor Revenue Estimates and Forecasts 2020-2031

2.2 Global Prostate-Specific Membrane Antigen(PSMA) Inhibitor Revenue by Region

2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031

2.2.2 Historical and Forecasted Revenue by Region (2020--2031)

2.2.3 Global Revenue Market Share by Region (2020-2031)

2.3 Global Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales Estimates and Forecasts 2020-2031

2.4 Global Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales by Region

2.4.1 Sales Comparison: 2020 VS 2024 VS 2031

2.4.2 Historical and Forecasted Sales by Region (2020-2031)

2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends

2.4.4 Global Sales Market Share by Region (2020-2031)

3 Global Production Analysis

3.1 Global Prostate-Specific Membrane Antigen(PSMA) Inhibitor Production Capacity and Utilization Rates (2020–2031)

3.2 Regional Production: Comparative Analysis (2020 VS 2024 VS 2031)

3.3 Regional Production Dynamics

3.3.1 Historic Production by Region (2020-2025)

3.3.2 Forecasted Production by Region (2026-2031)

3.3.3 Production Market Share by Region (2020-2031)

3.3.4 Regulatory and Trade Policy Impact on Production

3.3.5 Production Capacity Enablers and Constraints

3.4 Key Regional Production Hubs

3.4.1 North America

3.4.2 Europe

3.4.3 China

3.4.4 Japan

4 Competition by Manufacturers

4.1 Global Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales by Manufacturers

4.1.1 Global Sales Volume by Manufacturers (2020-2025)

4.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)

4.2 Global Prostate-Specific Membrane Antigen(PSMA) Inhibitor Manufacturer Revenue Rankings and Tiers

4.2.1 Global Revenue (Value) by Manufacturers (2020-2025)

4.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)

4.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)

4.3 Manufacturer Profitability Profiles and Pricing Strategies

4.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)

4.3.2 Manufacturer-Level Price Trends (2020-2025)

4.4 Key Manufacturers Manufacturing Base and Headquarters

4.5 Main Product Type Market Size by Manufacturers

4.5.1 Small Molecule Inhibitors Market Size by Manufacturers

4.5.2 Peptide Inhibitors Market Size by Manufacturers

4.5.3 Other Market Size by Manufacturers

4.6 Global Prostate-Specific Membrane Antigen(PSMA) Inhibitor Market Concentration and Dynamics

4.6.1 Global Market Concentration (CR5 and HHI)

4.6.2 Entrant/Exit Impact Analysis

4.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment

5 Global Product Segmentation Analysis

5.1 Global Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales Performance by Type

5.1.1 Global Historical and Forecasted Sales by Type (2020-2031)

5.1.2 Global Sales Market Share by Type (2020-2031)

5.2 Global Prostate-Specific Membrane Antigen(PSMA) Inhibitor Revenue Trends by Type

5.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)

5.2.2 Global Revenue Market Share by Type (2020-2031)

5.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)

5.4 Product Technology Differentiation

5.5 Subtype Dynamics: Growth Leaders, Profitability and Risk

5.5.1 High-Growth Niches and Adoption Drivers

5.5.2 Profitability Hotspots and Cost Drivers

5.5.3 Substitution Threats

6 Global Downstream Application Analysis

6.1 Global Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales by Application

6.1.1 Global Historical and Forecasted Sales by Application (2020-2031)

6.1.2 Global Sales Market Share by Application (2020-2031)

6.1.3 High-Growth Application Identification

6.1.4 Emerging Application Case Studies

6.2 Global Prostate-Specific Membrane Antigen(PSMA) Inhibitor Revenue by Application

6.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)

6.2.2 Revenue Market Share by Application (2020-2031)

6.3 Global Pricing Dynamics by Application (2020-2031)

6.4 Downstream Customer Analysis

6.4.1 Top Customers by Region

6.4.2 Top Customers by Application

7 North America

7.1 North America Sales Volume and Revenue (2020-2031)

7.2 North America Key Manufacturers Sales Revenue in 2024

7.3 North America Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales and Revenue by Type (2020-2031)

7.4 North America Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales and Revenue by Application (2020-2031)

7.5 North America Growth Accelerators and Market Barriers

7.6 North America Prostate-Specific Membrane Antigen(PSMA) Inhibitor Market Size by Country

7.6.1 North America Revenue by Country

7.6.2 North America Sales Trends by Country

7.6.3 US

7.6.4 Canada

7.6.5 Mexico

8 Europe

8.1 Europe Sales Volume and Revenue (2020-2031)

8.2 Europe Key Manufacturers Sales Revenue in 2024

8.3 Europe Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales and Revenue by Type (2020-2031)

8.4 Europe Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales and Revenue by Application (2020-2031)

8.5 Europe Growth Accelerators and Market Barriers

8.6 Europe Prostate-Specific Membrane Antigen(PSMA) Inhibitor Market Size by Country

8.6.1 Europe Revenue by Country

8.6.2 Europe Sales Trends by Country

8.6.3 Germany

8.6.4 France

8.6.5 U.K.

8.6.6 Italy

8.6.7 Russia

9 Asia-Pacific

9.1 Asia-Pacific Sales Volume and Revenue (2020-2031)

9.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024

9.3 Asia-Pacific Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales and Revenue by Type (2020-2031)

9.4 Asia-Pacific Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales and Revenue by Application (2020-2031)

9.5 Asia-Pacific Prostate-Specific Membrane Antigen(PSMA) Inhibitor Market Size by Region

9.5.1 Asia-Pacific Revenue by Region

9.5.2 Asia-Pacific Sales Trends by Region

9.6 Asia-Pacific Growth Accelerators and Market Barriers

9.7 Southeast Asia

9.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)

9.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand

9.8 China

9.9 Japan

9.10 South Korea

9.11 China Taiwan

9.12 India

10 Central and South America

10.1 Central and South America Sales Volume and Revenue (2020-2031)

10.2 Central and South America Key Manufacturers Sales Revenue in 2024

10.3 Central and South America Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales and Revenue by Type (2020-2031)

10.4 Central and South America Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales and Revenue by Application (2020-2031)

10.5 Central and South America Investment Opportunities and Key Challenges

10.6 Central and South America Prostate-Specific Membrane Antigen(PSMA) Inhibitor Market Size by Country

10.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)

10.6.2 Brazil

10.6.3 Argentina

11 Middle East and Africa

11.1 Middle East and Africa Sales Volume and Revenue (2020-2031)

11.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024

11.3 Middle East and Africa Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales and Revenue by Type (2020-2031)

11.4 Middle East and Africa Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales and Revenue by Application (2020-2031)

11.5 Middle East and Africa Investment Opportunities and Key Challenges

11.6 Middle East and Africa Prostate-Specific Membrane Antigen(PSMA) Inhibitor Market Size by Country

11.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)

11.6.2 GCC Countries

11.6.3 Turkey

11.6.4 Egypt

11.6.5 South Africa

12 Corporate Profile

12.1 TargetMol

12.1.1 TargetMol Corporation Information

12.1.2 TargetMol Business Overview

12.1.3 TargetMol Prostate-Specific Membrane Antigen(PSMA) Inhibitor Product Models, Descriptions and Specifications

12.1.4 TargetMol Prostate-Specific Membrane Antigen(PSMA) Inhibitor Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.1.5 TargetMol Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales by Product in 2024

12.1.6 TargetMol Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales by Application in 2024

12.1.7 TargetMol Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales by Geographic Area in 2024

12.1.8 TargetMol Prostate-Specific Membrane Antigen(PSMA) Inhibitor SWOT Analysis

12.1.9 TargetMol Recent Developments

12.2 Merck KGaA

12.2.1 Merck KGaA Corporation Information

12.2.2 Merck KGaA Business Overview

12.2.3 Merck KGaA Prostate-Specific Membrane Antigen(PSMA) Inhibitor Product Models, Descriptions and Specifications

12.2.4 Merck KGaA Prostate-Specific Membrane Antigen(PSMA) Inhibitor Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.2.5 Merck KGaA Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales by Product in 2024

12.2.6 Merck KGaA Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales by Application in 2024

12.2.7 Merck KGaA Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales by Geographic Area in 2024

12.2.8 Merck KGaA Prostate-Specific Membrane Antigen(PSMA) Inhibitor SWOT Analysis

12.2.9 Merck KGaA Recent Developments

12.3 DC Chemicals

12.3.1 DC Chemicals Corporation Information

12.3.2 DC Chemicals Business Overview

12.3.3 DC Chemicals Prostate-Specific Membrane Antigen(PSMA) Inhibitor Product Models, Descriptions and Specifications

12.3.4 DC Chemicals Prostate-Specific Membrane Antigen(PSMA) Inhibitor Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.3.5 DC Chemicals Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales by Product in 2024

12.3.6 DC Chemicals Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales by Application in 2024

12.3.7 DC Chemicals Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales by Geographic Area in 2024

12.3.8 DC Chemicals Prostate-Specific Membrane Antigen(PSMA) Inhibitor SWOT Analysis

12.3.9 DC Chemicals Recent Developments

12.4 Biorbyt

12.4.1 Biorbyt Corporation Information

12.4.2 Biorbyt Business Overview

12.4.3 Biorbyt Prostate-Specific Membrane Antigen(PSMA) Inhibitor Product Models, Descriptions and Specifications

12.4.4 Biorbyt Prostate-Specific Membrane Antigen(PSMA) Inhibitor Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.4.5 Biorbyt Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales by Product in 2024

12.4.6 Biorbyt Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales by Application in 2024

12.4.7 Biorbyt Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales by Geographic Area in 2024

12.4.8 Biorbyt Prostate-Specific Membrane Antigen(PSMA) Inhibitor SWOT Analysis

12.4.9 Biorbyt Recent Developments

12.5 MedChemExpress

12.5.1 MedChemExpress Corporation Information

12.5.2 MedChemExpress Business Overview

12.5.3 MedChemExpress Prostate-Specific Membrane Antigen(PSMA) Inhibitor Product Models, Descriptions and Specifications

12.5.4 MedChemExpress Prostate-Specific Membrane Antigen(PSMA) Inhibitor Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.5.5 MedChemExpress Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales by Product in 2024

12.5.6 MedChemExpress Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales by Application in 2024

12.5.7 MedChemExpress Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales by Geographic Area in 2024

12.5.8 MedChemExpress Prostate-Specific Membrane Antigen(PSMA) Inhibitor SWOT Analysis

12.5.9 MedChemExpress Recent Developments

12.6 QYAOBIO

12.6.1 QYAOBIO Corporation Information

12.6.2 QYAOBIO Business Overview

12.6.3 QYAOBIO Prostate-Specific Membrane Antigen(PSMA) Inhibitor Product Models, Descriptions and Specifications

12.6.4 QYAOBIO Prostate-Specific Membrane Antigen(PSMA) Inhibitor Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.6.5 QYAOBIO Recent Developments

12.7 ACROBiosystems Group

12.7.1 ACROBiosystems Group Corporation Information

12.7.2 ACROBiosystems Group Business Overview

12.7.3 ACROBiosystems Group Prostate-Specific Membrane Antigen(PSMA) Inhibitor Product Models, Descriptions and Specifications

12.7.4 ACROBiosystems Group Prostate-Specific Membrane Antigen(PSMA) Inhibitor Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.7.5 ACROBiosystems Group Recent Developments

12.8 Shanghai Apeptide Co

12.8.1 Shanghai Apeptide Co Corporation Information

12.8.2 Shanghai Apeptide Co Business Overview

12.8.3 Shanghai Apeptide Co Prostate-Specific Membrane Antigen(PSMA) Inhibitor Product Models, Descriptions and Specifications

12.8.4 Shanghai Apeptide Co Prostate-Specific Membrane Antigen(PSMA) Inhibitor Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.8.5 Shanghai Apeptide Co Recent Developments

12.9 Xi'an Ruixi Biotechnology Co., Ltd.

12.9.1 Xi'an Ruixi Biotechnology Co., Ltd. Corporation Information

12.9.2 Xi'an Ruixi Biotechnology Co., Ltd. Business Overview

12.9.3 Xi'an Ruixi Biotechnology Co., Ltd. Prostate-Specific Membrane Antigen(PSMA) Inhibitor Product Models, Descriptions and Specifications

12.9.4 Xi'an Ruixi Biotechnology Co., Ltd. Prostate-Specific Membrane Antigen(PSMA) Inhibitor Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.9.5 Xi'an Ruixi Biotechnology Co., Ltd. Recent Developments

12.10 SNDPHARM TSCHNOLOFY

12.10.1 SNDPHARM TSCHNOLOFY Corporation Information

12.10.2 SNDPHARM TSCHNOLOFY Business Overview

12.10.3 SNDPHARM TSCHNOLOFY Prostate-Specific Membrane Antigen(PSMA) Inhibitor Product Models, Descriptions and Specifications

12.10.4 SNDPHARM TSCHNOLOFY Prostate-Specific Membrane Antigen(PSMA) Inhibitor Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.10.5 SNDPHARM TSCHNOLOFY Recent Developments

12.11 Hangzhou MolCore BioPharmatech

12.11.1 Hangzhou MolCore BioPharmatech Corporation Information

12.11.2 Hangzhou MolCore BioPharmatech Business Overview

12.11.3 Hangzhou MolCore BioPharmatech Prostate-Specific Membrane Antigen(PSMA) Inhibitor Product Models, Descriptions and Specifications

12.11.4 Hangzhou MolCore BioPharmatech Prostate-Specific Membrane Antigen(PSMA) Inhibitor Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)

12.11.5 Hangzhou MolCore BioPharmatech Recent Developments

13 Value Chain and Supply-Chain Analysis

13.1 Prostate-Specific Membrane Antigen(PSMA) Inhibitor Industry Chain

13.2 Prostate-Specific Membrane Antigen(PSMA) Inhibitor Upstream Materials Analysis

13.2.1 Raw Materials

13.2.2 Key Suppliers Market Share & Risk Assessment

13.3 Prostate-Specific Membrane Antigen(PSMA) Inhibitor Integrated Production Analysis

13.3.1 Manufacturing Footprint Analysis

13.3.2 Production Technology Overview

13.3.3 Regional Cost Drivers

13.4 Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales Channels and Distribution Networks

13.4.1 Sales Channels

13.4.2 Distributors

14 Prostate-Specific Membrane Antigen(PSMA) Inhibitor Market Dynamics

14.1 Industry Trends and Evolution

14.2 Market Growth Drivers and Emerging Opportunities

14.3 Market Challenges, Risks, and Restraints

15 Key Findings in the Global Prostate-Specific Membrane Antigen(PSMA) Inhibitor Study

16 Appendix

16.1 Research Methodology

16.1.1 Methodology/Research Approach

16.1.1.1 Research Programs/Design

16.1.1.2 Market Size Estimation

16.1.1.3 Market Breakdown and Data Triangulation

16.1.2 Data Source

16.1.2.1 Secondary Sources

16.1.2.2 Primary Sources

16.2 Author Details

FEATURED COMPANIES

Xi'an Ruixi Biotechnology Co., Ltd.

Hangzhou MolCore BioPharmatech

SNDPHARM TSCHNOLOFY

List of Tables

Table 1. Global Prostate-Specific Membrane Antigen(PSMA) Inhibitor Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)

Table 2. Global Prostate-Specific Membrane Antigen(PSMA) Inhibitor Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)

Table 3. Global Prostate-Specific Membrane Antigen(PSMA) Inhibitor Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 4. Global Prostate-Specific Membrane Antigen(PSMA) Inhibitor Revenue by Region (2020-2025) & (US$ Million)

Table 5. Global Prostate-Specific Membrane Antigen(PSMA) Inhibitor Revenue by Region (2026-2031) & (US$ Million)

Table 6. Global Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (kg)

Table 7. Global Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales by Region (2020-2025) & (kg)

Table 8. Global Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales by Region (2026-2031) & (kg)

Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 10. Global Prostate-Specific Membrane Antigen(PSMA) Inhibitor Production Growth Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (kg)

Table 11. Global Prostate-Specific Membrane Antigen(PSMA) Inhibitor Production by Region (2020-2025) & (kg)

Table 12. Global Prostate-Specific Membrane Antigen(PSMA) Inhibitor Production by Region (2026-2031) & (kg)

Table 13. Global Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales by Manufacturers (2020-2025) & (kg)

Table 14. Global Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales Share by Manufacturers (2020-2025)

Table 15. Global Prostate-Specific Membrane Antigen(PSMA) Inhibitor Revenue by Manufacturers (2020-2025) & (US$ Million)

Table 16. Global Prostate-Specific Membrane Antigen(PSMA) Inhibitor Revenue Market Share by Manufacturers (2020-2025)

Table 17. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)

Table 18. Global Prostate-Specific Membrane Antigen(PSMA) Inhibitor by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Prostate-Specific Membrane Antigen(PSMA) Inhibitor as of 2024)

Table 19. Global Prostate-Specific Membrane Antigen(PSMA) Inhibitor Average Gross Margin (%) by Manufacturer (2020 VS 2024)

Table 20. Global Prostate-Specific Membrane Antigen(PSMA) Inhibitor Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/g)

Table 21. Key Manufacturers Prostate-Specific Membrane Antigen(PSMA) Inhibitor Manufacturing Base and Headquarters

Table 22. Global Prostate-Specific Membrane Antigen(PSMA) Inhibitor Market Concentration Ratio (CR5 and HHI)

Table 23. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis

Table 24. Key Mergers & Acquisitions, Expansion Plans, R&D Investment

Table 25. Global Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales by Type (2020-2025) & (kg)

Table 26. Global Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales by Type (2026-2031) & (kg)

Table 27. Global Prostate-Specific Membrane Antigen(PSMA) Inhibitor Revenue by Type (2020-2025) & (US$ Million)

Table 28. Global Prostate-Specific Membrane Antigen(PSMA) Inhibitor Revenue by Type (2026-2031) & (US$ Million)

Table 29. Global Prostate-Specific Membrane Antigen(PSMA) Inhibitor ASP by Type (2020-2031) & (US$/g)

Table 30. Technical Specifications by Key Product Type

Table 31. Global Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales by Application (2020-2025) & (kg)

Table 32. Global Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales by Application (2026-2031) & (kg)

Table 33. Prostate-Specific Membrane Antigen(PSMA) Inhibitor High-Growth Sectors Demand CAGR (2024-2031)

Table 34. Global Prostate-Specific Membrane Antigen(PSMA) Inhibitor Revenue by Application (2020-2025) & (US$ Million)

Table 35. Global Prostate-Specific Membrane Antigen(PSMA) Inhibitor Revenue by Application (2026-2031) & (US$ Million)

Table 36. Global Prostate-Specific Membrane Antigen(PSMA) Inhibitor ASP by Application (2020-2031) & (US$/g)

Table 37. Top Customers by Region

Table 38. Top Customers by Application

Table 39. North America Prostate-Specific Membrane Antigen(PSMA) Inhibitor Growth Accelerators and Market Barriers

Table 40. North America Prostate-Specific Membrane Antigen(PSMA) Inhibitor Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 41. North America Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales (kg) by Country (2020 VS 2024 VS 2031)

Table 42. Europe Prostate-Specific Membrane Antigen(PSMA) Inhibitor Growth Accelerators and Market Barriers

Table 43. Europe Prostate-Specific Membrane Antigen(PSMA) Inhibitor Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 44. Europe Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales (kg) by Country (2020 VS 2024 VS 2031)

Table 45. Asia-Pacific Prostate-Specific Membrane Antigen(PSMA) Inhibitor Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Asia-Pacific Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales (kg) by Country (2020 VS 2024 VS 2031)

Table 47. Asia-Pacific Prostate-Specific Membrane Antigen(PSMA) Inhibitor Growth Accelerators and Market Barriers

Table 48. Southeast Asia Prostate-Specific Membrane Antigen(PSMA) Inhibitor Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 49. Central and South America Prostate-Specific Membrane Antigen(PSMA) Inhibitor Investment Opportunities and Key Challenges

Table 50. Central and South America Prostate-Specific Membrane Antigen(PSMA) Inhibitor Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 51. Middle East and Africa Prostate-Specific Membrane Antigen(PSMA) Inhibitor Investment Opportunities and Key Challenges

Table 52. Middle East and Africa Prostate-Specific Membrane Antigen(PSMA) Inhibitor Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 53. TargetMol Corporation Information

Table 54. TargetMol Description and Major Businesses

Table 55. TargetMol Product Models, Descriptions and Specifications

Table 56. TargetMol Capacity, Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)

Table 57. TargetMol Sales Value Proportion by Product in 2024

Table 58. TargetMol Sales Value Proportion by Application in 2024

Table 59. TargetMol Sales Value Proportion by Geographic Area in 2024

Table 60. TargetMol Prostate-Specific Membrane Antigen(PSMA) Inhibitor SWOT Analysis

Table 61. TargetMol Recent Developments

Table 62. Merck KGaA Corporation Information

Table 63. Merck KGaA Description and Major Businesses

Table 64. Merck KGaA Product Models, Descriptions and Specifications

Table 65. Merck KGaA Capacity, Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)

Table 66. Merck KGaA Sales Value Proportion by Product in 2024

Table 67. Merck KGaA Sales Value Proportion by Application in 2024

Table 68. Merck KGaA Sales Value Proportion by Geographic Area in 2024

Table 69. Merck KGaA Prostate-Specific Membrane Antigen(PSMA) Inhibitor SWOT Analysis

Table 70. Merck KGaA Recent Developments

Table 71. DC Chemicals Corporation Information

Table 72. DC Chemicals Description and Major Businesses

Table 73. DC Chemicals Product Models, Descriptions and Specifications

Table 74. DC Chemicals Capacity, Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)

Table 75. DC Chemicals Sales Value Proportion by Product in 2024

Table 76. DC Chemicals Sales Value Proportion by Application in 2024

Table 77. DC Chemicals Sales Value Proportion by Geographic Area in 2024

Table 78. DC Chemicals Prostate-Specific Membrane Antigen(PSMA) Inhibitor SWOT Analysis

Table 79. DC Chemicals Recent Developments

Table 80. Biorbyt Corporation Information

Table 81. Biorbyt Description and Major Businesses

Table 82. Biorbyt Product Models, Descriptions and Specifications

Table 83. Biorbyt Capacity, Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)

Table 84. Biorbyt Sales Value Proportion by Product in 2024

Table 85. Biorbyt Sales Value Proportion by Application in 2024

Table 86. Biorbyt Sales Value Proportion by Geographic Area in 2024

Table 87. Biorbyt Prostate-Specific Membrane Antigen(PSMA) Inhibitor SWOT Analysis

Table 88. Biorbyt Recent Developments

Table 89. MedChemExpress Corporation Information

Table 90. MedChemExpress Description and Major Businesses

Table 91. MedChemExpress Product Models, Descriptions and Specifications

Table 92. MedChemExpress Capacity, Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)

Table 93. MedChemExpress Sales Value Proportion by Product in 2024

Table 94. MedChemExpress Sales Value Proportion by Application in 2024

Table 95. MedChemExpress Sales Value Proportion by Geographic Area in 2024

Table 96. MedChemExpress Prostate-Specific Membrane Antigen(PSMA) Inhibitor SWOT Analysis

Table 97. MedChemExpress Recent Developments

Table 98. QYAOBIO Corporation Information

Table 99. QYAOBIO Description and Major Businesses

Table 100. QYAOBIO Product Models, Descriptions and Specifications

Table 101. QYAOBIO Capacity, Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)

Table 102. QYAOBIO Recent Developments

Table 103. ACROBiosystems Group Corporation Information

Table 104. ACROBiosystems Group Description and Major Businesses

Table 105. ACROBiosystems Group Product Models, Descriptions and Specifications

Table 106. ACROBiosystems Group Capacity, Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)

Table 107. ACROBiosystems Group Recent Developments

Table 108. Shanghai Apeptide Co Corporation Information

Table 109. Shanghai Apeptide Co Description and Major Businesses

Table 110. Shanghai Apeptide Co Product Models, Descriptions and Specifications

Table 111. Shanghai Apeptide Co Capacity, Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)

Table 112. Shanghai Apeptide Co Recent Developments

Table 113. Xi'an Ruixi Biotechnology Co., Ltd. Corporation Information

Table 114. Xi'an Ruixi Biotechnology Co., Ltd. Description and Major Businesses

Table 115. Xi'an Ruixi Biotechnology Co., Ltd. Product Models, Descriptions and Specifications

Table 116. Xi'an Ruixi Biotechnology Co., Ltd. Capacity, Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)

Table 117. Xi'an Ruixi Biotechnology Co., Ltd. Recent Developments

Table 118. SNDPHARM TSCHNOLOFY Corporation Information

Table 119. SNDPHARM TSCHNOLOFY Description and Major Businesses

Table 120. SNDPHARM TSCHNOLOFY Product Models, Descriptions and Specifications

Table 121. SNDPHARM TSCHNOLOFY Capacity, Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)

Table 122. SNDPHARM TSCHNOLOFY Recent Developments

Table 123. Hangzhou MolCore BioPharmatech Corporation Information

Table 124. Hangzhou MolCore BioPharmatech Description and Major Businesses

Table 125. Hangzhou MolCore BioPharmatech Product Models, Descriptions and Specifications

Table 126. Hangzhou MolCore BioPharmatech Capacity, Sales (kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2020-2025)

Table 127. Hangzhou MolCore BioPharmatech Recent Developments

Table 128. Key Raw Materials Distribution

Table 129. Raw Materials Key Suppliers

Table 130. Critical Raw Material Supplier Concentration (2024) & Risk Index

Table 131. Milestones in Production Technology Evolution

Table 132. Distributors List

Table 133. Market Trends and Market Evolution

Table 134. Market Drivers and Opportunities

Table 135. Market Challenges, Risks, and Restraints

Table 136. Research Programs/Design for This Report

Table 137. Key Data Information from Secondary Sources

Table 138. Key Data Information from Primary Sources

List of Figures

Figure 1. Prostate-Specific Membrane Antigen(PSMA) Inhibitor Product Picture

Figure 2. Global Prostate-Specific Membrane Antigen(PSMA) Inhibitor Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)

Figure 3. Small Molecule Inhibitors Product Picture

Figure 4. Peptide Inhibitors Product Picture

Figure 5. Other Product Picture

Figure 6. Global Prostate-Specific Membrane Antigen(PSMA) Inhibitor Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)

Figure 7. Scientific Research

Figure 8. Pharmaceuticals

Figure 9. Prostate-Specific Membrane Antigen(PSMA) Inhibitor Report Years Considered

Figure 10. Global Prostate-Specific Membrane Antigen(PSMA) Inhibitor Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 11. Global Prostate-Specific Membrane Antigen(PSMA) Inhibitor Revenue (2020-2031) & (US$ Million)

Figure 12. Global Prostate-Specific Membrane Antigen(PSMA) Inhibitor Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Figure 13. Global Prostate-Specific Membrane Antigen(PSMA) Inhibitor Revenue Market Share by Region (2020-2031)

Figure 14. Global Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales (2020-2031) & (kg)

Figure 15. Global Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales (CAGR) by Region (2020-2031) (kg)

Figure 16. Global Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales Market Share by Region (2020-2031)

Figure 17. Global Prostate-Specific Membrane Antigen(PSMA) Inhibitor Capacity, Production and Utilization (2020-2031) & (kg)

Figure 18. Global Prostate-Specific Membrane Antigen(PSMA) Inhibitor Production Trend by Region (2020-2031) (kg)

Figure 19. Global Prostate-Specific Membrane Antigen(PSMA) Inhibitor Production Market Share by Region (2020-2031)

Figure 20. Production Capacity Enablers & Constraints

Figure 21. Prostate-Specific Membrane Antigen(PSMA) Inhibitor Production Growth Rate in North America (2020-2031) & (kg)

Figure 22. Prostate-Specific Membrane Antigen(PSMA) Inhibitor Production Growth Rate in Europe (2020-2031) & (kg)

Figure 23. Prostate-Specific Membrane Antigen(PSMA) Inhibitor Production Growth Rate in China (2020-2031) & (kg)

Figure 24. Prostate-Specific Membrane Antigen(PSMA) Inhibitor Production Growth Rate in Japan (2020-2031) & (kg)

Figure 25. Top 5 and Top 10 Manufacturers Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales Volume Market Share in 2024

Figure 26. Global Prostate-Specific Membrane Antigen(PSMA) Inhibitor Revenue Market Share Ranking (2024)

Figure 27. Tier Distribution by Revenue Contribution (2020 VS 2024)

Figure 28. Small Molecule Inhibitors Revenue Market Share by Manufacturer in 2024

Figure 29. Peptide Inhibitors Revenue Market Share by Manufacturer in 2024

Figure 30. Other Revenue Market Share by Manufacturer in 2024

Figure 31. Type Eight Revenue Market Share by Manufacturer in 2024

Figure 32. Type Nine Revenue Market Share by Manufacturer in 2024

Figure 33. Global Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales Market Share by Type (2020-2031)

Figure 34. Global Prostate-Specific Membrane Antigen(PSMA) Inhibitor Revenue Market Share by Type (2020-2031)

Figure 35. Global Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales Market Share by Application (2020-2031)

Figure 36. Global Prostate-Specific Membrane Antigen(PSMA) Inhibitor Revenue Market Share by Application (2020-2031)

Figure 37. North America Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales YoY (2020-2031) & (kg)

Figure 38. North America Prostate-Specific Membrane Antigen(PSMA) Inhibitor Revenue YoY (2020-2031) & (US$ Million)

Figure 39. North America Top 5 Manufacturers Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales Revenue (US$ Million) in 2024

Figure 40. North America Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales Volume (kg) by Type (2020- 2031)

Figure 41. North America Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales Revenue (US$ Million) by Type (2020 - 2031)

Figure 42. North America Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales Volume (kg) by Application (2020-2031)

Figure 43. North America Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales Revenue (US$ Million) by Application (2020-2031)

Figure 44. US Prostate-Specific Membrane Antigen(PSMA) Inhibitor Revenue (2020-2031) & (US$ Million)

Figure 45. Canada Prostate-Specific Membrane Antigen(PSMA) Inhibitor Revenue (2020-2031) & (US$ Million)

Figure 46. Mexico Prostate-Specific Membrane Antigen(PSMA) Inhibitor Revenue (2020-2031) & (US$ Million)

Figure 47. Europe Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales YoY (2020-2031) & (kg)

Figure 48. Europe Prostate-Specific Membrane Antigen(PSMA) Inhibitor Revenue YoY (2020-2031) & (US$ Million)

Figure 49. Europe Top 5 Manufacturers Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales Revenue (US$ Million) in 2024

Figure 50. Europe Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales Volume (kg) by Type (2020-2031)

Figure 51. Europe Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales Revenue (US$ Million) by Type (2020-2031)

Figure 52. Europe Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales Volume (kg) by Application (2020-2031)

Figure 53. Europe Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales Revenue (US$ Million) by Application (2020-2031)

Figure 54. Germany Prostate-Specific Membrane Antigen(PSMA) Inhibitor Revenue (2020-2031) & (US$ Million)

Figure 55. France Prostate-Specific Membrane Antigen(PSMA) Inhibitor Revenue (2020-2031) & (US$ Million)

Figure 56. U.K. Prostate-Specific Membrane Antigen(PSMA) Inhibitor Revenue (2020-2031) & (US$ Million)

Figure 57. Italy Prostate-Specific Membrane Antigen(PSMA) Inhibitor Revenue (2020-2031) & (US$ Million)

Figure 58. Russia Prostate-Specific Membrane Antigen(PSMA) Inhibitor Revenue (2020-2031) & (US$ Million)

Figure 59. Asia-Pacific Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales YoY (2020-2031) & (kg)

Figure 60. Asia-Pacific Prostate-Specific Membrane Antigen(PSMA) Inhibitor Revenue YoY (2020-2031) & (US$ Million)

Figure 61. Asia-Pacific Top 8 Manufacturers Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales Revenue (US$ Million) in 2024

Figure 62. Asia-Pacific Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales Volume (kg) by Type (2020- 2031)

Figure 63. Asia-Pacific Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales Revenue (US$ Million) by Type (2020- 2031)

Figure 64. Asia-Pacific Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales Volume (kg) by Application (2020-2031)

Figure 65. Asia-Pacific Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales Revenue (US$ Million) by Application (2020-2031)

Figure 66. Indonesia Prostate-Specific Membrane Antigen(PSMA) Inhibitor Revenue (2020-2031) & (US$ Million)

Figure 67. Japan Prostate-Specific Membrane Antigen(PSMA) Inhibitor Revenue (2020-2031) & (US$ Million)

Figure 68. South Korea Prostate-Specific Membrane Antigen(PSMA) Inhibitor Revenue (2020-2031) & (US$ Million)

Figure 69. China Taiwan Prostate-Specific Membrane Antigen(PSMA) Inhibitor Revenue (2020-2031) & (US$ Million)

Figure 70. India Prostate-Specific Membrane Antigen(PSMA) Inhibitor Revenue (2020-2031) & (US$ Million)

Figure 71. Central and South America Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales YoY (2020-2031) & (kg)

Figure 72. Central and South America Prostate-Specific Membrane Antigen(PSMA) Inhibitor Revenue YoY (2020-2031) & (US$ Million)

Figure 73. Central and South America Top 5 Manufacturers Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales Revenue (US$ Million) in 2024

Figure 74. Central and South America Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales Volume (kg) by Type (2021-2031)

Figure 75. Central and South America Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales Revenue (US$ Million) by Type (2020-2031)

Figure 76. Central and South America Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales Volume (kg) by Application (2020-2031)

Figure 77. Central and South America Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales Revenue (US$ Million) by Application (2020-2031)

Figure 78. Brazil Prostate-Specific Membrane Antigen(PSMA) Inhibitor Revenue (2020-2025) & (US$ Million)

Figure 79. Argentina Prostate-Specific Membrane Antigen(PSMA) Inhibitor Revenue (2020-2025) & (US$ Million)

Figure 80. Middle East, and Africa Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales YoY (2020-2031) & (kg)

Figure 81. Middle East and Africa Prostate-Specific Membrane Antigen(PSMA) Inhibitor Revenue YoY (2020-2031) & (US$ Million)

Figure 82. Middle East and Africa Top 5 Manufacturers Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales Revenue (US$ Million) in 2024

Figure 83. Middle East and Africa Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales Volume (kg) by Type (2021-2031)

Figure 84. South America Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales Revenue (US$ Million) by Type (2020-2031)

Figure 85. Middle East and Africa Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales Volume (kg) by Application (2020-2031)

Figure 86. Middle East and Africa Prostate-Specific Membrane Antigen(PSMA) Inhibitor Sales Revenue (US$ Million) by Application (2020-2031)

Figure 87. GCC Countries Prostate-Specific Membrane Antigen(PSMA) Inhibitor Revenue (2020-2025) & (US$ Million)

Figure 88. Turkey Prostate-Specific Membrane Antigen(PSMA) Inhibitor Revenue (2020-2025) & (US$ Million)

Figure 89. Egypt Prostate-Specific Membrane Antigen(PSMA) Inhibitor Revenue (2020-2025) & (US$ Million)

Figure 90. South Africa Prostate-Specific Membrane Antigen(PSMA) Inhibitor Revenue (2020-2025) & (US$ Million)

Figure 91. Prostate-Specific Membrane Antigen(PSMA) Inhibitor Industry Chain Mapping

Figure 92. Regional Prostate-Specific Membrane Antigen(PSMA) Inhibitor Manufacturing Base Distribution (%)

Figure 93. Prostate-Specific Membrane Antigen(PSMA) Inhibitor Production Process

Figure 94. Regional Prostate-Specific Membrane Antigen(PSMA) Inhibitor Production Cost Structure

Figure 95. Channels of Distribution (Direct Vs Distribution)

Figure 96. Bottom-up and Top-down Approaches for This Report

Figure 97. Data Triangulation

Figure 98. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$4900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

RELATED REPORTS

Global Pharmacy Chatbot Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-10T20319

Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Global Inline Pharmaceutical Packaging Leak Detection System Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-6Q20319

Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Global Radiological Marker Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-35Z19949

Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Global Pharmaceutical Biomanufacturing Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-26E19785

Wed Dec 03 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions